[Federal Register Volume 81, Number 229 (Tuesday, November 29, 2016)]
[Notices]
[Pages 85982-85983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28698]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Development and
Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial
Agonists for the Treatment of Opioid Use Disorder, Schizophrenia
Bipolar Disorder and Tetrahydrocannabinol Dependence
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Drug Abuse, National Institutes of
Health, Department of Health and Human Services, is contemplating the
grant of an Exclusive Patent License to Braeburn Pharmaceuticals, Inc.
(``Braeburn'') located in Princeton, New Jersey to practice the
inventions embodied in the patent applications listed in the
SUPPLEMENTARY INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before
December 14, 2016 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Martha Lubet, Ph.D., Licensing and Patenting
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville,
MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-276-5504;
Email: [email protected].
SUPPLEMENTARY INFORMATION: United States Provisional Patent Application
No. 62/307600, filed March 14, 2016, entitled ``Dopamine D3 Receptor
Selective Antagonists/Partial Agonists; Methods of Making and Use
Thereof'' [HHS Reference No. E-053-2016]; and U.S. 8,748,608,
Australian 2007354861, and Canadian 2690789 (which claim priority to
PCT/US2007/71412 filed June 15, 2007) entitled ``4-phenylpiperazine
derivatives with functionalized linkers as dopamine D3 selective
ligands and methods of use'' [HHS Reference No. E-128-2006] (and U.S.
and foreign patent applications or patents claiming priority to the
aforementioned applications).
With respect to persons who have an obligation to assign their
right, title and interest to the Government of the United States of
America, the patent rights in these inventions have been assigned to
the Government of the United States of America.
The prospective Exclusive Patent License territory may be worldwide
for the treatment opioid use disorder schizophrenia, bipolar disorder
and tetrahydrocannabinol dependence, as set forth in the Licensed
Patent Rights.
The present invention describes Dopamine D3 receptor ligands and
methods of using the ligands to treat substance use disorders,
schizophrenia, bipolar disorder and other mental disorders.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective Exclusive Patent License will be royalty
bearing and may be granted unless within fifteen (15) days from the
date of this published notice, the National Institute on Drug Abuse
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
[[Page 85983]]
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated Exclusive Patent License.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: November 23, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2016-28698 Filed 11-28-16; 8:45 am]
BILLING CODE 4140-01-P